These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2093441)

  • 41. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
    Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam S; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF;
    Ann Rheum Dis; 2011 Mar; 70(3):469-75. PubMed ID: 21149498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Drug therapy of rheumatoid arthritis].
    Arndt U; Rittmeister M; Möller B
    Orthopade; 2003 Dec; 32(12):1095-103. PubMed ID: 14655006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pharmacogenomics of the immunosuppressive agents].
    Taniguchi A; Urano W; Tanaka E; Kitamura Y; Saito M; Akama H; Yamanak H; Saito T; Kamatani N
    Nihon Rinsho Meneki Gakkai Kaishi; 2002 Feb; 25(1):105-9. PubMed ID: 11963167
    [No Abstract]   [Full Text] [Related]  

  • 44. Measuring methotrexate polyglutamates.
    Goodman S
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S24-6. PubMed ID: 21044429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Methotrexate: first-line or second-line immunomodulator?
    Fraser AG
    Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):225-31. PubMed ID: 12610315
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Methotrexate in the treatment of rheumatoid arthritis].
    Agadzhanian GN; Balabanova RM
    Ter Arkh; 1986; 58(7):114-6. PubMed ID: 3532399
    [No Abstract]   [Full Text] [Related]  

  • 47. Some aspects of anti-inflammatory action of immunosuppressive drugs.
    Tsukada W; Akimoto T; Mizushima Y
    Jpn J Pharmacol; 1974 Aug; 24(4):583-8. PubMed ID: 4455967
    [No Abstract]   [Full Text] [Related]  

  • 48. Methotrexate-associated Lymphoproliferative Disease with Multiple Pulmonary Nodules in a Patient with Rheumatoid Arthritis.
    Suemori K; Hasegawa H; Ishizaki J; Matsumoto T; Onishi S; Sada E; Sugita A; Yasukawa M
    Intern Med; 2015; 54(11):1421-5. PubMed ID: 26028000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination therapy in rheumatoid arthritis.
    Schwarzer AC; Arnold MH; Brooks PM
    Baillieres Clin Rheumatol; 1990 Dec; 4(3):663-85. PubMed ID: 1982708
    [No Abstract]   [Full Text] [Related]  

  • 50. [Methotrexate in rheumatoid polyarthritis. Review of the literature].
    Sauvezie B; Dubost JJ; Garandeau A; Rampon S
    Rev Rhum Mal Osteoartic; 1987; 54(7-9):607-15. PubMed ID: 3313672
    [No Abstract]   [Full Text] [Related]  

  • 51. [Rheumatoid arthritis. Begin early aggressive therapy].
    Fortschr Med; 1997 Feb; 115(6):23. PubMed ID: 9173006
    [No Abstract]   [Full Text] [Related]  

  • 52. Methotrexate pharmacogenetics in rheumatoid arthritis.
    Brinker RR; Ranganathan P
    Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S33-9. PubMed ID: 21044431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of interaction between flucloxacillin and methotrexate in patients with rheumatoid arthritis.
    Herrick AL; Grennan DM; Griffen K; Aarons L; Gifford LA
    Br J Clin Pharmacol; 1996 Mar; 41(3):223-7. PubMed ID: 8866922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis.
    Wilske KR; Healey LA
    J Rheumatol Suppl; 1990 Nov; 25():4-7. PubMed ID: 2273521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Level of evidence for therapeutic drug monitoring of low dose methotrexate in inflammatory diseases].
    Verdier MC; Tribut O; Bodeau S; Rihouey D; Bentué-Ferrer D
    Therapie; 2011; 66(1):63-72. PubMed ID: 21466780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methotrexate therapy in rheumatoid arthritis. Current status.
    Wilke WS; Mackenzie AH
    Drugs; 1986 Aug; 32(2):103-13. PubMed ID: 3743465
    [No Abstract]   [Full Text] [Related]  

  • 57. Visceral leishmaniasis in a rheumatoid arthritis patient receiving methotrexate.
    Reina D; Cerdà D; Güell E; Martínez Montauti J; Pineda A; Corominas H
    Reumatol Clin; 2017; 13(6):354-356. PubMed ID: 27523470
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Methotrexate-associated, early-onset pancytopenia in rheumatoid arthritis.
    Doolittle GC; Simpson KM; Lindsley HB
    Arch Intern Med; 1989 Jun; 149(6):1430-1. PubMed ID: 2730263
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.
    Salach RH; Cash JM
    Clin Ther; 1994; 16(6):912-22; discussion 911. PubMed ID: 7697687
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Anakinra for therapy of rheumatoid arthritis].
    Tomoo T; Sumida T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():534-7. PubMed ID: 15799413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.